BDX Stock Forecast & Price Target

Becton Dickinson is attractive because its core portfolio is broad, recurring, and defensively positioned, with more than 60% of revenue from the United States and 90% of hospital patients touched by a BD product. The separation of Biosciences and Diagnostics sharpened the company into a pure-play MedTech platform, while the ~$4B cash distribution, 2.9x net leverage targeting 2.5x, and buybacks as the #1 near-term priority should enhance shareholder returns. Operational momentum also supports the bullish view, as FQ3 revenue rose 4.4% cc to $4,983M, adjusted operating margin held at 24.9%, and BD Excellence is driving about 8% plant productivity despite tariff headwinds.

Becton Dickinson is facing a fragile post-separation setup, with management’s own downside case implying weaker revenue growth at “new BD,” margin pressure from business investments, tariffs, and M&A dilution, and lower shareholder returns despite at least half of the roughly $4 billion Bioscience/Diagnostics cash being earmarked for repurchases. The outlook is further pressured by persistent operating drags in Alaris, China, and vaccines, where Alaris alone is expected to be about a 100 bp headwind in FY'26 and around 200 bp in FY'27, while China remains a meaningful risk even as it is only 4% of New BD revenue. More than 60% of revenue comes from the U.S., so the company also remains exposed to domestic reimbursement changes, funding cuts, competition across Medical and Interventional, and broader inflation and supply-chain disruption, limiting confidence in upside catalysts.